Literature DB >> 27815332

Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents.

Marcella Bassetto1, Salvatore Ferla1, Pieter Leyssen2, Johan Neyts2, Mark M Yerukhimovich3, David N Frick3, Rachel O'Donnell1, Andrea Brancale1.   

Abstract

BACKGROUND: Despite the great progress made in the last 10 years, alternative strategies might help improving definitive treatment options against hepatitis C virus infection.
METHODS: With the aim of identifying novel inhibitors of the hepatitis C virus-1b replication targeting the viral NS3 helicase, the structures of previously reported symmetrical inhibitors of this enzyme were rationally modified, and according to docking-based studies, four novel scaffolds were selected for synthesis and evaluation in the hepatitis C virus-1b subgenomic replicon assay.
RESULTS: Among the newly designed compounds, one new structural family was found to inhibit the hepatitis C virus-1b replication in the micromolar range. This scaffold was chosen for further exploration and different novel analogues were synthesised and evaluated.
CONCLUSIONS: Different new inhibitors of the hepatitis C virus genotype 1b replication were identified. Some of the new compounds show mild inhibition of the NS3 helicase enzyme.

Entities:  

Keywords:  Hepatitis C virus; inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27815332      PMCID: PMC5890509          DOI: 10.1177/2040206616676353

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  23 in total

Review 1.  Hepatitis C virus replicons: potential role for drug development.

Authors:  Ralf Bartenschlager
Journal:  Nat Rev Drug Discov       Date:  2002-11       Impact factor: 84.694

Review 2.  The role of resistance in HCV treatment.

Authors:  Johannes Vermehren; Christoph Sarrazin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

3.  Hepatitis C virus NS3 and simian virus 40 T antigen helicases displace streptavidin from 5'-biotinylated oligonucleotides but not from 3'-biotinylated oligonucleotides: evidence for directional bias in translocation on single-stranded DNA.

Authors:  Patrick D Morris; Alicia K Byrd; Alan J Tackett; Craig E Cameron; Poonam Tanega; Robert Ott; Ellen Fanning; Kevin D Raney
Journal:  Biochemistry       Date:  2002-02-19       Impact factor: 3.162

4.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding.

Authors:  J L Kim; K A Morgenstern; J P Griffith; M D Dwyer; J A Thomson; M A Murcko; C Lin; P R Caron
Journal:  Structure       Date:  1998-01-15       Impact factor: 5.006

5.  Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase.

Authors:  Angela M I Lam; David N Frick
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Structure-based mutagenesis study of hepatitis C virus NS3 helicase.

Authors:  C Lin; J L Kim
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  Aurintricarboxylic acid modulates the affinity of hepatitis C virus NS3 helicase for both nucleic acid and ATP.

Authors:  William R Shadrick; Sourav Mukherjee; Alicia M Hanson; Noreena L Sweeney; David N Frick
Journal:  Biochemistry       Date:  2013-08-26       Impact factor: 3.162

8.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.

Authors:  A A Kolykhalov; K Mihalik; S M Feinstone; C M Rice
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 9.  Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Authors:  Min Gao
Journal:  Curr Opin Virol       Date:  2013-07-27       Impact factor: 7.090

Review 10.  HCV NS5A inhibitors in development.

Authors:  Anna Suk-Fong Lok
Journal:  Clin Liver Dis       Date:  2013-02       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.